Physiology and Pathology of Cytokine: Commercial Production and Medical Use by Zdravkovic, Nemanja et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 3
Physiology and Pathology of Cytokine: Commercial
Production and Medical Use
Nemanja Zdravkovic, Mirko Rosic,
Mitar Lutovac and Vladimir Zdravkovic
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.72200
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
Nemanja Zdravkovic, Mirko Rosic, Mitar Lutovac and 
Vladimir Zdravkovic
Additional information is available at the end of the chapter
Abstract
Cytokines are small, short-lived proteins secreted by many different cell types. As sig-
naling molecules, cytokines provide communication between cells and play a crucial 
role in modulating innate and adaptive immune response. The family of cytokines 
includes interferons, interleukins, chemokines, mesenchymal growth factors, tumor 
necrosis factor family and adipokines. Interferons (IFNs) are a multigene family of 
inducible cytokines with antiviral, antiproliferative, and immunomodulatory func-
tion. Recombinant DNA technology can be useful in the production of human IFNs. 
This process includes fermentation, purification, and formation of the final product. 
Interleukins are classified in families based on sequence homology, receptor-binding 
properties, biological function, and cellular sources. TNF and IL-1 are considered to 
be key mediators of inflammatory response, while IL-6 plays a key role in the transi-
tion from acute to chronic inflammation. The inhibition of TNF includes administra-
tion of anti-TNF antibody and TNF receptor (TNFR). The reduction of IL-1 level can 
be achieved by the administration of anti-IL-1 antibody or IL-1 receptor antagonist 
(IL-1Ra), and the reduction of IL-6 level in the treatment of chronic inflammatory dis-
eases can be achieved by the administration of anti-IL-6 antibody and anti-IL-6 receptor 
antibody. Recombinant cytokines and cytokine antagonists (antibodies and receptors) 
can be used in treating many different diseases.
Keywords: cytokines, interleukins, interferons, TNF
1. Introduction
Cytokines are low molecular weight proteins or glycoproteins secreted by a number of cell 
types. The term cytokine is made up of two parts: cyto (cell) and kine (movement) [1]. As 
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 signaling molecules, cytokines provide communication between cells and play a crucial role 
in modulating of the innate and adaptive immune response (Table 1).
Nomenclature of cytokines was created either according to the type of cells which secrete 
them (in this case named interleukins and adipokines) or biological activity (in this case 
Family Members Functions
IL-1 family
IL-1 subfamily Agonist activity
IL-1α (IL-1F1) Induction of proinflammatory response
Th17 cell differentiation
IL-1β (IL-1F2) Induction of proinflammatory response
Th17 cell differentiation
IL-33(IL-1F11) Acts as an alarmin
Induction of Th2 response
Activation of ILC2 cells
Th1 cell differentiation dependent on IL-12
Induction of Treg cells
Receptor antagonists
IL-1Ra (IL-1F3) Antagonism of IL-1
IL-18 subfamily Agonist activity
IL-18(IL-1F4) Induction of IFN-γ in presence of IL-12
Enhances NK cell cytotoxicity
Promoting Th1 or Th2 cell responses depending
cytokine milieu
Activation and cytokines release from neutrophils
Antiinflammatory activity
IL-37 (IL-1F7) Suppression the production of proinflamatory 
cytokines
Inhibition of dendritic cells (DCs) function (foremost 
through stimulation of TGF-β)
IL-36 subfamily Agonist activity
IL-36α(IL-1F6) Promoting Th1 and Th17 cell responses (skin, lungs, 
kidneys)
IL-36β (IL-1F8) Promoting Th1 and Th17 cell responses (joints)
IL-36γ(IL-1F9) Promoting Th1 and Th17 cell responses (lungs)
Receptor antagonists
IL-36Ra(IL-1F5) Antagonism of IL-36-α, IL-36-β and IL-36γ
Antiinflammatory brain action via induction of IL-4 
expression in glia cells
Physiology and Pathology of Immunology34
Family Members Functions
IL-38(IL-1F10) Antagonism of IL-36-α, IL-36-β and IL-36γ
Inhibits the production of IL-17 and IL-22
Inhibits the production of IL-8 induced by IL-36γ
Common γ chain cytokine 
family
IL-2 Proliferation and differentiation into effector and 
memory T cells
Development of Treg cells
Proliferation of B cells
Proliferation and differentiation of NK cells
IL-4 Th2 cell differentiation
IgE class switching
Antagonise the effects of IFN-γ
Alternative activation of macrophages (M2 phenotype)
Upregulation of class II MHC molecules expression on 
B cells and monocytes
Upregulation of FcεRII (CD23) and IL-4R
Survival factor for B and T cells
Role in tissue adhesion and inflammation
IL-7 Proliferation of early T and B cell progenitors
Naive and memory T cell survival
Development of γδT cells (VDJ recombination of 
TCRγ)
Induction of CTLs and LAK cells
IL-9 CD4+ T cells and mast cells growth factor
Proliferation of CD8+ T cells and mast cells
Inhibition of Th1 cytokines
Promotes Th17 cell differentiation
IgE production
Chemokine and mucus production in bronchial 
epithelial cells
IL-15 Induction of Th1 and Th17 responses
Activation of T cell (decreased TCR activation 
threshold)
Survival and proliferation of memory CD8+ T cells
Loss of Treg cells- and TGF-β immunoregulation
Suppression of IL-2 induced AICD of T cells
Differentiation of γδT cells
Proliferation and activation of NK cells
Homeostasis of NK and NKT cells
Induction of LAK cells
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Family Members Functions
IL-21 Regulation of B cell proliferation, differentiation and 
apoptosis
Antibody isotype balance (increased IgG and 
decreased IgE)
Generation of long-lived plasma cells and T cell-
dependent antigen responses and memory
T cell and NK cell proliferation
Increases cytotoxic activity of NK cells and CTL cells
Induces the differentiation of T follicular helper (TFH) cells
Expansion of Th17 cells
Inhibits DC activation and maturation
IL-6 family
IL-6 Synthesis of acute phase proteins in liver
Inducing secretion of chemokines: CCL2, CCL8, 
CXCL5, CXCL6
Induction of neutrophil apoptosis
Switching from neutrophil to monocyte recruitment
Transition from innate to acquired immunity
Direct mediator of T cell migration
T cell differentiation, activation and survival
B cell differentiation and production of IgG, IgM, IgA
Survival of hematopoietic stem cells and early progenitors
Proliferation and differentiation of myeloid, erythroid, 
megakaryocyte progenitors
Survival factor for neuronal cells
IL-11 Synthesis of acute phase proteins in liver
Growth factor for myeloid, erythroid, megakaryocyte 
progenitors
Bone remodeling
Protects epithelial cells and connective tissue
Inhibition of macrophage activity
Inhibition of adipogenesis
Promotion of neuronal development
IL-31 Induction of IL-1β, IL-6, IL-8, GRO-α (CXCL1), MCP-1 
(CCL2) and DC-CK1 (CCL18) production in eosinophils
Increased chemokines mRNA expression (GRO-α 
(CXCL1), TARC (CCL17), MIP-3β (CCL19), MDC 
(CCL22), MIP-3 (CCL23), MIP-1β (CCL4)) in keratinocytes
Antiapoptotic effect on eosinophils
Expression of growth factors and chemokines in 
epithelial cells
Inhibition of proliferation and apoptosis in epithelial 
cells
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Family Members Functions
Leukemia inhibitory factor 
(LIF)
Self-renewal and block in differentiation embryonic 
stem cell
Embryonic implantation (receptive state of 
endometrial, the interaction between endometrial 
and embryo, stromal decidualization, the 
invasion of blastocyst, blastocyst development, 
infiltration of uterine leukocytes, synthesis of 
prostaglandins)
Anti-inflammatory effect
Neuronal development
Oncostatin M
(OSM)
Maintenance of erythroid and megakaryocyte 
progenitor pools in BM by regulation  
hematopoietic cytokine production in  
stromal cells and direct effect on  
erythrocytic and megakaryocytic  
progenitors
Tumor suppression
Neuronal development
IL-10 family
IL-10 Immune suppression
Inhibition of expression IL-12, costimulators , 
and class II MHC molecules on macrophages 
and DCs
Inhibition of proliferation CD4+ T cells and production 
of IL-2, IFN-γ, IL-4, IL-5 and TNF-α
Enhancing Treg cells function (suppressing 
autoreactive T cells)
Reduces immune suppression of autoreactive B cells
and enhances antibody production
IL-20 subfamily IL-19 Enhances the production of Th2 cytokines
Induces IL-6, IL-8 and IL-10 production in  
monocytes
Alternative activation of macrophages  
(M2 phenotype)
Induction of angiogenesis
Role in skin inflammation (psoriasis)
Production of antimicrobial peptides (S100A7 
(also known as psoriasin), S100A8, S100A9, 
and β-defensins) and barrier function increase
IL-20 Role in skin inflammation (psoriasis)
Development of hematopoietic cells
Production of antimicrobial peptides (S100A7 
(also known as psoriasin), S100A8, S100A9, and 
β-defensins) and barrier function increase
Inhibition of neutrophil phagocytosis, granule 
exocytosis,and migration
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Family Members Functions
IL-22 Controlling the intestinal microbiota
Production of antimicrobial peptides  
(S100A7 (also known as psoriasin),  
S100A8, S100A9, and β-defensins) and  
barrier function increase
Wound healing
Tissue regeneration (intestine, liver, thymus,  
pancreas and kidneys)
Role in skin inflammation (psoriasis)
IL-24 Tumor suppression (loss of proliferative capacity)
Production of antimicrobial peptides  
(S100A7 (also known as psoriasin),  
S100A8, S100A9, and β-defensins) and  
barrier function increase
Role in skin inflammation (psoriasis)
IL-26 Production of proinflammatory cytokines (IL-1β, IL-6, 
TNF and CCL20)
Th17 cell differentiation
Direct killing of bacteria
See Type III interferons IL-28A (IFN-λ2)
IL-28B (IFN-λ3)
IL-29 (IFN-λ1)
IL-12 family
IL-12 Th1 cell differentiation
Increases cytotoxic activity of NK cells and CD8+ T 
cells and production of IFN-γ
Antiangiogenic effect
IL-23 Th17 cell expansion, maintaining  
activation and secretion of IL-17A,  
IL-17F, IL-22 and GM-CSF
Dependent pathogenicity of Th17 cells
Stimulation of macrophages to produce  
TNF, IL-1
IL-27 Pro- and anti-inflammatory effects  
(induction of Th1 response and suppressive  
effect on CD4+ T cell production of IL-2,  
inhibition of Th2, Th17 and iTreg cells)
Limits the intensity and duration of innate and 
adaptive immune responses
IL-35 Induction of Treg cells proliferation
Inhibition of Th17 response
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Family Members Functions
IL-17 family
IL-17A
IL-17F
Induction of proinflamatory cytokines, chemokines, and
metalloproteases (controlling bacterial and fungal 
infection)
Modulation of viral infection
Recruitment of neutrophils
IL-17B
IL-17C
IL-17D
Induction of proinflamatory cytokines,  
chemokines, and
metalloproteases
IL-25 (IL17E) Induction of Th2 response
Th2 like cytokines
IL-5 Differentiation and function of myeloid cells
Increment of chemotactic activity and adhesion 
capacity on eosinophils
Remodeling and wound healing
IL-13 Switching to IgE
Antagonises the effects of IFN-γ
Upregulation of FcεRII (CD23) and class II MHC 
molecules expression on B cells and monocytes
Alternative activation of macrophages (M2 
phenotype)
Activation of eosinophils and mast cells
Recruitment and survival of eosinophils
Defense against parasite infections (mucus 
production)
Chemokine activities
IL-8 Chemoattractant for neutrophils, NK cells, T cells, 
basophils, eosinophils
Induces phagocytosis
Mobilisation of hematopoietic stem cells
Angiogenesis
IL-16 Chemoattractant for cells with CD4 molecule
Modulation of T cell response
Non-classified
IL-3 Induces maturation of all hematopoietic lineages
Activation of basophils
Activation and survival of eosinophils
IL-14 Induces growth and proliferation of B cells 
and inhibits antibody secretion
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Family Members Functions
IL-32 Induction of TNF-α, IL-6 and IL-8
Induction of apoptosis
IL-34 Differentiation and viability of monocytes 
and macrophages
Type I interferons
IFN-α
(13 subtypes)
Antiviral state
Increases the expression of class I MHC molecules
Activation of NK cells
IFN-β Antiviral state
Increases the expression of class I MHC  
molecules
Activation of NK cells
IFN-κ
IFN-ω
IFN-ɛ
IFN-δ (pigs)
IFN-ζ
IFN-τ (ruminant)
IFN-v
Antiviral response
Type II interferons
IFN-γ Th1 cell differentiation
Classical activation of macrophages (increased 
microbicidal functions)
Promotes cytotoxic activity
Isotype switching to opsonisation and complement-
fixing IgG subclasses (established in mice)
Upregulation of class I and class II MHC  
molecules
Increases antigen processing and presentation 
to T cells
Antiviral properties
Inhibition of cell growth
Proapoptotic effects
Type III interferons
IL-28A (IFN-λ2)
IL-28B (IFN-λ3)
Antiviral response
Promotes cytotoxic activity
IL-29 (IFN-λ1) Antiviral response
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named interferons, chemokines, mesenchymal growth factors and tumor necrosis factor fam-
ily). This nomenclature is still used [2]. There are several basic common properties of cyto-
kines which are important in understanding their effect in the human body:
1. Synthesis of cytokine is mainly induced by various stimuli which act on cells. Also they 
can exist in preformed granules which are constitutively produced and secreted from 
cells.
2. Cytokines achieve their effects by binding with high affinity to specific membrane recep-
tors on cells. Therefore, cells show a relatively small number of specific cytokine receptors 
(100–1000 per cell). In other words, very low concentrations of cytokines can trigger bio-
logical effects in cells. Cellular response to the effects of cytokines is well regulated and it 
is reflected in the changes of gene expression in target cells resulting in the expression of 
new functions.
3. Cytokines exert effects on different types of cells (the same cells express a variety of cy-
tokine receptors), or one cytokine can exert many different biological effects. This cytokine 
action is called pleiotropy. Also, several cytokines share the same functional effects, and 
various cytokines can have the same or similar biological activity (various cytokines acti-
vate the same signaling pathways) which is called redundancy [3].
4. Cytokines affect the synthesis and the activity of other cytokines, acting antagonistically, 
additively or synergistically.
Family Members Functions
IFN-λ4 Antiviral response
Impairs HCV antiviral program or clearance by 
impeding receptor binding of the other members of 
the IFN-λ family
TNF superfamily TNF Induction of inflammation (vasodilatation, edema, 
facilitation of the adhesion of leukocytes, production 
of reactive oxygen species)
Induction of intravascular thrombosis
Fever occurrence
Induces secretion of IL-6 from leukocytes
Loss of appetite, wasting of muscle and fat cells 
(cachexia)
Induction of insulin resistance
Inhibits myocardial contractility and vascular smooth 
muscle tone (low blood pressure)
Stimulates capillary leak
Table 1. Characteristics of cytokines.
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5. Cytokine activity can be autocrine (on the very cell that secretes it), paracrine (on sur-
rounding cells) and endocrine (in distant cites from the production). Basic characteristics 
of cytokines suggest that their implementation achieves complex effects which are often 
accompanied by numerous side effects.
2. Interferons
Interferons (IFNs) consist of multigene family of inducible cytokines with predominantly 
antiviral activity [4]. Interferons were detected more than 50 years ago as a soluble substance 
which inhibits the replication of influenza virus. They were named after their ability to inter-
fere (hinder) the replication in host cells protecting healthy cells from viral infection [5]. The 
family of interferons is now described as a key component of innate immune response and 
the first line of defense against viral infections. Interferons are proteins that synthesize and 
produce host cells in response to the presence of various pathogens: viruses, bacteria and par-
asites. As signaling molecules they provide communication between cells for the purpose of 
activating and directing the immune response in order to eliminate the pathogen in the most 
effective way. Due to the fact that interferons belong to the cytokine family, they influence 
the processes of proliferation, differentiation and apoptosis, and exhibit a number of immu-
nomodulatory functions. According to the type of receptor complex via which they transmit 
the signal, all interferons are classified into three classes (Type I, II and III). This means that 
interferons can achieve their activity over three receptor complexes. Type I (IFN-α, IFN-β) 
and type III interferons have been identified as antiviral types, and type II (IFN-γ) is known 
as the immune interferon.
Antiviral and antiproliferative activity of interferons, as well as their ability to modulate 
immune and inflammatory responses, make them highly applicable in medical treatment [6]. 
There are many preparations of interferons which are approved for clinical use. Further clini-
cal studies are conducted presently. It is expected that the obtained results will enable a wider 
application of interferons for medical purposes. Although it became clear in XX century that 
the possibilities for therapeutic application of interferons are huge, the following issues had 
to be resolved in order to find their wider application in medicine:
1. An extremely low level of interferons is produced in the human body.
2. Interferons show species specificity, which implies that only human interferons can be 
used for human clinical treatments.
Since interferons were grown from human leukocytes present in blood transfusion stocks 
until the 1970s of the last century, their massive production was virtually untenable. In 
fact, this method provided a mixture of various types and subtypes of interferons in differ-
ent quantities. However, clinical studies conducted with modest amounts of insufficiently 
treated interferon preparations have yielded encouraging results. A significant production 
of interferons was achieved by mammalian cell lines used in the late 1970s. A variety of 
tumor cell lines was tested first and it was revealed that Namalwa cell line (a type of human 
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lymphoblastic cell) produced a large amount of interferons [7]. The exposure of these cells to 
certain viruses (typically Sendai virus) caused an increased production of IFN. Subsequent 
analysis showed that the final product contains thirteen subtypes of IFN-α, which is why it 
was necessary to introduce new production technologies. Nowadays, the recombinant DNA 
technology is used to obtain individual interferon (sub) types. The production of the desired 
interferon is achieved by insertion of specific genes using vectors for interferons (usually 
a virus) in mammalian cell lines (Chinese Hamster Ovary - CHO, monkey kidney, etc.), 
bacteria Escherichia coli (E. coli) or fungi. Although around 70% of pharmaceutical recombi-
nant proteins currently used for medical purposes is produced in mammalian cells, inter-
ferons are produced mainly in E. coli. The purification of interferons aims to obtain a final 
product with 99% level purity, which is mainly achieved by using chromatographic tech-
niques (metal-chelate affinity chromatography, exclusion chromatography (gel filtration), 
ion-exchange chromatography). Finally, the quality and quantity of interferons are checked 
by monoclonal antibodies and their effects are analyzed on biological material by different 
biological assays.
2.1. Production and medical use of IFN-α
Interferon production process includes the fermentation process, purification and the for-
mation of the final product. Fermentation is conducted in specially designed vessels made 
of stainless steel. This process involves transfer and expression of genes in E. coli and the 
subsequent intracytoplasmic protein production of the inserted gene. Thus, recombinant pro-
teins constitute intracytoplasmic accumulation of inclusion bodies. Homogenization E. coli 
and centrifugation, followed by a chromatographic purification process, need to be done in 
order to prepare inclusion bodies. The crystallization method is used for the final purification 
of interferons. The crystallized product is then dissolved in a phosphate buffer which contains 
glycine and human albumin (carriers of an active substance). Finally, lyophilization and pack-
aging of the product is done.
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There are several significant advantages achieved by the modification of interferons. Recom-
binant interferon modification is achieved by the process of “pegylation.” This process was 
first described by Frank Davis and Abraham Abuchowski and his associates in 1977 [8]. In 
contrast to the modification process of drug formulation (using colloidal systems or osmotic 
pumps), the process of interferon pegylation involves covalently binding polyethylene gly-
col (PEG) polymer chain to the amino group of interferons, which significantly improves its 
pharmacokinetic and pharmacodynamic characteristics [9]. Many existing pharmacological 
limitations of interferons are overcome by the process pegylation. Native PEG is an inert, non-
toxic polymer with two terminal hydroxyl groups. Chemically active form of PEG molecule 
is obtained by modifying the terminal hydroxyl group (substitution process of a hydroxyl 
group with reactive (functional) one). The incubation of purified interferon with methoxy-
polyethylene glycol (chemically active form of PEG) spontaneously forms covalent bonds [10]. 
There are different configurations of PEG molecules today, including linear and branched 
structures of various molecular weights. Formation of stable (covalent) bonds in the process of 
pegylation of interferon is necessary for a long-term preservation of incurred pharmacologi-
cal changes. Resultant molecules of interferon are predominantly monopegylated with small 
impurities of di-, and non-pegylated molecules. Sodium phosphate, saccharose and polysor-
bate are used as carriers of the active substance for the pegylated product in lyophilized form.
After subcutaneous administration IFN-α is rapidly absorbed and the peak of serum con-
centration is reached 7–12 hours after which its concentration decreases rapidly. As half-life 
of IFN-α is 3–8 hours, its serum concentration falls below detection limit within 24 hours 
after administration [11]. Since the administration of IFN-α is conducted 3 times a week, the 
desired serum concentration is not maintained in most intervals between applications.
Different linear and branched structures of PEG molecules are used for the pegylation of IFN-α, 
so that the resulting preparations exhibit different pharmacokinetic and pharmacodynamic 
characteristics which are improved in comparison to standard IFN-α. PEG group protects IFN-α 
from enzymatic degradation, prolongs the absorption period at the administration site of sub-
cutaneous injection and reduces its clearance from the body, so the period to reach maximum 
concentration is significantly prolonged (80 hours). Taking into consideration the above men-
tioned, it is clear that IFN-α concentration in blood is higher and more constant for a much lon-
ger period of time when compared to standard IFN-α. These pharmacokinetic properties enable 
once-a-week subcutaneous administration of pegylated IFN-α to achieve and maintain the con-
centration in blood that provides the desired effectiveness (desired effects are time and concen-
tration dependent). Pegylation of IFN-α greatly improves its pharmacodynamic characteristics, 
and testing shows 100 times stronger antiviral activity and 20 times stronger antitumor activity. 
Nowadays, IFN-α is used in the treatment of hepatitis B and C, chronic myeloid leukemia, malig-
nant melanoma, non-Hodgkin’s lymphoma, Kaposi’s sarcoma, and other diseases (Table 2).
2.2. Production and medical use of IFN-β
There are several preparations made of IFN-β used for therapeutic purposes. Some of them 
were made by recombinant DNA technology in E. coli, but nowadays CHO cell line is mostly 
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used in their production [12]. Recombinant human IFN-β produced in CHO cell line (rhIFN-
β-1a) is glycosylated and it has the same amino acid sequence as natural IFN-β [13, 14]. 
Although E. coli does not generate glycosylation of IFN-β [15], this deficiency does not affect 
the efficiency of its therapeutic applications. IFN-β is presently used in the treatment of mul-
tiple sclerosis. However, in IFN-β glycans play an important role in the protein stabilization 
and thus enhance its biological activity [16] (Table 3).
Generic name Trade name Treatment Year of first FDA approval Company
IFN-β − 1a Avonex Relapsing multiple sclerosis
High risk for MS
1996 Biogen
IDEC
IFN-β − 1b Betaseron Relapsing multiple sclerosis
High risk for MS
1993 Berlex
IFN-β − 1b Extavia Relapsing multiple sclerosis 2009 Novartis
Table 3. IFN-β approved by FDA for therapeutic use.
Generic name Trade name Treatment Year of first FDA 
approval
Company
IFN-α − con-1 Infergen Chronic hepatitis C 1997 Amgen
IFN-α − n3, leukocyte 
derived
Alferon-N Condylomata acuminata 1989 Hemisperx
Biopharma
IFN-α − 2a, pegylated Pegasys Chronic hepatitis C
Chronic hepatitis B
2002 Roche
IFN-α − 2a, recombinant Roferon-A Chronic hepatitis C
Hairy cell leukemia
Kaposi’s sarcoma
Chronic myeloid leukemia
1986 Roche
IFN-α − 2b, pegylated PEG-Intron Chronic hepatitis C 2001 Schering-Plow
IFN-α − 2b, pegylated Sylatron Malignant melanoma 2011 Schering-Plow
IFN-α − 2b, recombinant Intron-A Hairy cell leukemia
Kaposi’s sarcoma
Chronic hepatitis B/C
Malignant melanoma
Follicular lymphoma
Condylomata acuminata
1997 Schering-Plow
Table 2. IFN-α approved by FDA for therapeutic use.
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2.3. Production and medical use of IFN-γ
IFN-γ preparations are made by recombinant DNA technology in bacteria E. coli. Despite 
the fact that recombinant human IFN-γ is not glycosylated [17], its biological activity is not 
affected. It is used for the treatment of chronic granulomatous disease (Table 4).
2.4. Side effects of interferon application
Administration of interferons can cause many side effects [18].
Application of IFN-α causes increased temperature, chills and headache. These reactions are 
often manifested a few weeks after the application and paracetamol is simultaneously applied 
to alleviate them. Severe cases develop anorexia, insomnia, cardiovascular complications and 
autoimmune reactions, which requires immediate termination of its application.
Application of IFN-β causes increased temperature, chills and headache. Severe cases develop 
hypersensitivity reactions, depression and menstrual disorders.
Application of IFN-γ causes increased temperature, chills and headache. Severe cases develop 
heart failure, metabolic disorders and disorientation.
3. Interleukins
More than 40 interleukins with different properties are known today. Interleukins are classi-
fied in families based on sequence homology, receptor-binding properties, biological function 
and cellular sources.
There are 38 interleukins which are designated by the abbreviation IL (from Interleukin) and 
Arabic numbers [19]. Interleukins are produced by various types of body cells, wherein the 
specific interleukins (IL-1) can be secreted by up to 20 different cell types. Most cells capa-
ble of synthesizing one interleukin are capable of synthesizing several different. Today, the 
recombinant DNA technology is used for interleukin production, enabling quantities suffi-
cient to meet demanding medical needs.
3.1. Production and medical use of interleukin 1 (IL-1)
IL-1 is a proinflammatory cytokine which stimulates the synthesis of substances involved in 
the induction of inflammation. Activated mononuclear phagocytes are the main cellular source 
Generic name Trade name Treatment Year of first FDA 
approval
Company
IFN-γ − 1b, 
bioengineered
Actimmune Chronic granulomatous 
disease
Malignant osteopetrosis
1990 Intermune Pharma
Table 4. IFN-γ approved by FDA for therapeutic use.
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of IL-1. When secreted in small quantities, IL-1 acts as a paracrine mediator of local inflam-
mation, while in larger amounts the endocrine effect can induce body temperature increase, 
synthesis of acute-phase proteins in the liver and the production of neutrophils and platelets 
in the bone marrow. In diseases with the elevated level of IL-1 it is important to decrease IL-1 
level due to its effect in the induction of inflammation [20]. It has been shown that prepara-
tions which reduce the level of IL-1 are therapeutically useful when administered alone or, 
more preferably, in the combination with low doses of other therapeutic agents. In accordance 
with the above, the reduction of IL-1 level can be achieved by the administration of:
1. Anti-IL-1 antibody
2. The IL-1 receptor antagonist (IL-1Ra)
3.1.1. Anti-IL-1 antibody
Canakinumab is a human anti-IL-1ß monoclonal antibody which is administered subcutane-
ously for the treatment of syndromes associated with periodic cryopyrin (CAPS—cryopyrin 
associated periodic syndromes). The main sign of CAPS is urticaria with neutrophilia, accom-
panied by high fever, headache and arthralgia.
3.1.2. The IL-1 receptor antagonist (IL-1Ra)
Anakinra/Kineret is a recombinant, nonglycosylated form of human interleukin-1 receptor 
antagonist (IL-1Ra). Anakinra is different from native human IL-1Ra as it is non-glycosyl-
ated and may contain an additional N-terminal methionine residue at its amino-terminus, 
as the result of its production by recombinant DNA technology in prokaryotic system 
(E. coli). In people suffering from rheumatoid arthritis an elevated level of IL-1 is present in the 
synovial fluid of joints affected. IL-1 shows negative effects on the joints and bones, which 
include degradation of cartilage and stimulates bone resorption. Therefore, in patients suf-
fering from rheumatoid arthritis the subcutaneous injection of 100 mg (0.67 ml) of Anakinra 
is administered daily. The following substances are present as carriers of active substance in 
the final product: sodium citrate (1.29 mg), ethylenediaminetetraacetic acid (EDTA) (0.12 mg), 
sodium chloride (5.48 mg) and polysorbate 80 (0.70 mg). It is also approved to be applied in 
the treatment of Neonatal-Onset Multisystem Inflammatory Disease (severe form Cryopyrin-
Associated Periodic Syndromes).
3.2. Production and medical use of interleukin 2 (IL-2)
As it was the case with most other cytokines, the use of IL-2 for medical purposes was initially 
impractical because of small production quantities. Some transformed cell lines, particularly 
cell line Jurkat (T cell leukemia), produced IL-2 in larger quantities [21]. The largest amounts 
of IL-2 used in initial studies were obtained from this source. The production of significant 
amounts of IL-2 is possible by the development of recombinant DNA technology. Today, 
complementary DNA (cDNA) to the IL-2 gene is expressed in many cell lines, while E. coli 
was used at the beginning (absence of glycosylation of the recombinant product does not alter 
biological activity of IL-2).
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Basiliximab (anti-IL-2Rα (CD25); chimeric monoclonal antibody) is produced in a cell line 
Sp2/0 and is administered intravenously to patients after kidney transplantation. Basiliximab 
and cyclosporine are administered in the treatment of kidney transplant [22]. It is important 
to note that studies have shown that basiliximab slows cyclosporine elimination from the 
body (it is believed that cytochrome P450 plays an important role in this process).
Daclizumab (anti-IL-2Rα (CD25); humanized monoclonal antibody) was administered intra-
venously to patients after kidney transplantation. It was withdrawn from the market of the 
European Union and the United States of America in 2009.
Recombinant IL-2.
Proleukin (Aldesleukin) is indicated for the treatment of adults with metastatic renal cell 
carcinoma (year of first approval-1992) and metastatic melanoma (year of first approval-1998). 
Proleukin helps an increased production of several different components of the immune sys-
tem found in the blood, including T lymphocytes and natural killer cells. Proleukin should be 
restricted to patients with healthy heart and lung function. Proleukin can cause capillary leak 
syndrome and the treatment is associated with a reduced neutrophil chemotaxis and with an 
increased risk of disseminated infection, including sepsis.
3.3. Production and medical use of interleukin 6 (IL-6)
IL-6 has pro- and anti-inflammatory properties and plays a crucial role during the transition 
from innate to acquired immunity. It has the ability to stimulate neutrophil production, promote 
expansion and activation of T cells, the differentiation of B cells, and the regulation of the acute-
phase response [23]. Proteolytic shedding of IL-6Rα from invading neutrophils subsequently 
drives IL-6 trans-signaling in resident tissue cells, leading to a switch from neutrophil to mono-
cyte recruitment by suppressing mainly neutrophil-attracting (CXCL1, CXCL8 and CX3CL1) 
and enhancing mainly monocyte-attracting chemokines (CCL2, CCL8, CXCL5 and CXCL6), 
and cellular adhesion controlled by the lymph node–homing receptor CD62L, and modulates 
expression of adhesion molecules ICAM-1 and VCAM-1. Besides its role in attracting monocytes, 
IL-6 trans-signaling has been shown to skew monocyte differentiation toward macrophages by 
upregulating M-CSF receptor expression. The finding that IL-6 induces neutrophil apoptosis 
contributes to the resolution of acute neutrophil infiltration. Increased IL-6 level is often a better 
predictor of disease activity in the context of infection, autoimmunity or cancer than C-reactive 
protein [24, 25]. Consistent with the early description of IL-6 as a lymphocyte-stimulating factor, 
IL-6 deficiency leads to impaired innate and adaptive immunity to viral, parasitic and bacterial 
infection. Indeed, children with inhibitory autoantibodies to IL-6 develop recurrent staphylococ-
cal cellulitis and subcutaneous abscesses. While IL-6 has a protective role in many infections, the 
same activity can be key to the maintenance of chronic inflammation that includes rheumatoid 
arthritis and multicentric Castleman’s disease. The reduction of IL-6 level (Table 5) as the treat-
ment of chronic inflammatory diseases can be achieved by the administration of:
1. Anti-IL-6 antibody
2. Anti-IL-6 receptor antibody
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3.3.1. Anti-IL-6 antibody
Siltuximab is a chimeric immunoglobulin (IgG)1 monoclonal antibody that binds IL-6. IL-6 
antagonist is indicated for the treatment of patients with multicentric Castleman’s disease 
(MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 
(HHV-8) negative.
3.3.2. Anti-IL-6 receptor antibody
Sarilumab is a human immunoglobulin (IgG)1 monoclonal antibody which binds specifi-
cally to both soluble and membrane-bound IL-6 receptors (sIL-6Rα and mIL-6Rα) and inhib-
its IL-6-mediated signaling. It is administered subcutaneously in a dose of 200 mg once every 
2 weeks for the treatment of rheumatoid arthritis. By binding to IL-6Rα, sarilumab prevents 
the formation of high-affinity complex of IL-6 with IL-6Rα and thus blocks IL-6 signaling. As 
sarilumab blocks both mIL-6Rα and sIL-6Rα, it has the potential to inhibit both intra-articular 
and systemic IL-6 signaling. Patients treated with Sarilumab are at increased risk for develop-
ing serious infections.
3.4. Production and medical use of tumor necrosis factor (TNF)
Tumor necrosis factor (TNF) was originally described as a circulating protein which causes 
tumor necrosis (discovered in 1975 as endotoxin-induced glycoprotein which causes necrosis 
of sarcoma in mice). Human TNF was first produced in 1985 by recombinant DNA technology 
in E. coli [26]. Activated mononuclear phagocytes are the most important cellular source of 
TNF. TNF exerts a variety of effects on vascular endothelial cells and leukocytes. In response 
to TNF endothelial cells enhance the expression of different combinations of leukocyte adhe-
sion molecules (including E-selectin, ICAM-1 and VCAM-1), which in combination with the 
secretion of chemokines (IL-8, including, MCP-1 and IP-10) from peripheral blood leukocytes 
and endothelial cells induces chemotaxis of different populations of leukocytes to the site of 
inflammation apart from the recognition of the antigen. In addition, TNF stimulates microbi-
cidal activity of neutrophils and monocytes in order to eliminate the cause easier. Secreted in 
small amounts, TNF acts locally (autocrine and paracrine), primarily on vascular endothelial 
International 
nonproprietary name 
(INN)
Target Type Year of first 
EMA approval
Year of first 
FDA approval
Cell line Therapeutic indication
Tocilizumab IL-6R Humanized 
IgG1
2009 2010 CHO Rheumatoid arthritis
Juvenile idiopathic 
arthritis
Siltuximab IL-6 Chimeric 
IgG1
2014 2014 CHO Multicentric 
Castleman’s disease
Sarilumab IL-6R Human IgG1 2017 2017 CHO Rheumatoid arthritis
Table 5. Monoclonal antibodies target at IL-6/IL-6R approved by FDA and EMA for therapeutic use.
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cells and leukocytes. The effect of TNF on the endothelium and leukocytes is most likely cru-
cial for a successful local inflammatory response to microorganisms. TNF is produced in large 
quantities in severe infections. It enters the bloodstream and affects distant cites (endocrine), 
causing pathological and clinical effects on the body. Systemic effects caused due to exces-
sive TNF production or exogenous administration in high doses can induce increased body 
temperature, synthesis of acute-phase proteins in the liver, production of neutrophils and 
platelets in the bone marrow. TNF is presently considered a key mediator of inflammatory 
response which has a wide range of effects in inflammation, infection and response to tumors. 
In this respect, several approaches can be useful, and this includes the administration of:
1. Anti-TNF antibody
2. TNF receptor (TNFR)
3. TNF
3.4.1. Anti-TNF antibody
Infliximab is an anti-TNF-α antibody which binds TNF-α and blocks the inflammation 
induced by cytokine. Today it is successfully used in the treatment of rheumatoid arthritis, 
ankylosing spondylitis, Crohn’s disease, ulcerative colitis, etc.
Adalimumab and Golimumab are human anti-TNF-α antibodies which bind to TNF-α by 
blocking its activity. As TNF is a primary mediator of inflammation, these antibodies are very 
powerful anti-inflammatory agents.
Adalimumab has been successfully used in the treatment of rheumatoid arthritis, ankylosing 
spondylitis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, etc. It is administered in the 
treatment of rheumatoid arthritis and ankylosing spondylitis as a subcutaneous injection in a 
dose of 40 mg twice a month (in severe conditions once a week). In the treatment of Crohn’s 
disease starting dose is 80 mg, then 40 mg every other week (in severe conditions starting dose 
is 160 mg).
Golimumab has been successfully used in the treatment of rheumatoid arthritis, ankylosing 
spondylitis and psoriatic arthritis.
Certolizumab pegol is a humanized Fab fragment of a pegylated anti-TNF antibody pro-
duced by recombinant DNA technology in E. coli. It is used in the therapy of Crohn’s disease 
and rheumatoid arthritis. Pegylation of Fab fragments significantly improves distribution in 
tissues and prolongs the half-elimination to 14 days. The lack of Fc fragment in cells prevents 
the antibody binding to the protective FcRn receptor (Neonatal Fc receptor).
3.4.2. TNF receptor (TNFR)
Etanercept/Enbrel is a recombinant human hybrid protein in which extracellular domain of 
TNFR2 fuses with Fc fragment of IgG (Soluble p75 TNF receptor-Fc fusion). It is produced by 
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recombinant DNA technology in a CHO cell line. After the purification and addition of the 
carrier (mannitol, saccharose, and trometamol), the product is lyophilized. It is used for the 
treatment of rheumatoid arthritis (RA) by subcutaneous injection of 25 mg dose twice a week 
or 50 mg once a week. It is also applied in the treatment of juvenile idiopathic arthritis, anky-
lozing spondylitis, psoriatic arthritis, plaque psoriasis and plaque psoriasis in children ages 
4–17. Etanercept functions as a competitive inhibitor of TNF, because it prevents its binding to 
receptors present on cell surface. Side effects of etanercept include the development of infec-
tions and tumors, allergic reaction (hives, swelling of the face, etc.), headache and heart failure.
3.4.3. TNF
Tasonermin is a human TNF-α-1a produced by recombinant DNA technology in E. coli. The 
purified product is packed in tube vials (1 mg of active substance per bottle) as a lyophilizate. 
The carriers of active substance in the final product are sodium chloride, phosphate buffer 
and serum albumin. It is used in the treatment of soft tissue sarcoma on the limbs in order 
to prevent or postpone the amputation. Tasonermin is dissolved in physiological saline to a 
concentration of 0.2 mg/ml after which the tissue perfusion of the affected limb is done with 
3–4 mg of the substance for a period of 90 minutes. Side effects of tasonermin could be local 
(edem, nerve damage) and systemic (arrhythmia, nausea, liver damage) if it enters the sys-
temic circulation.
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